An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...
Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...
This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...
Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...
A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
